Skip to content
zameds

Fluticasone furoate

Schedule 2 to 4, conditions apply
Loading the molecular structure
C27H29F3O6S538.60 g/mol

[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-Difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 9854489.

Listing

Schedules
Schedule 2 to 4, conditions apply
Source
Consolidated Schedules 06 July 2026

Registered medicines

3 registered products listed

Counted through the register's ingredient index, which does not reach every record.

Registered products
NameBrandsDosagesApplicantsRegistrationsSchedule
Fluticasone furoateGenemist, Avamys, Revinty elipta, +6 more27.5 _g, 92/22 ug, 100 μg/ 62,5 μg/ 25 μg, 100 μg/ 62,5 μg/25 μg, +1 more3 applicants11 registrationsS4

Regulatory status

Where S2 to S4 sits on the scale

Depends on which listing applies

At the least restrictive, Schedule 2: a pharmacist can sell it directly, without a prescription. At the most restrictive, Schedule 4: prescription-only medicine. The listings below say which applies to which form, strength or pack size.

Schedule S2 to S4, as the Consolidated Schedules list it.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Fluticasone furoate

  • S4: Fluticasone furoate

    • except when intended for nasal administration, as an aqueous spray, in the short-term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses. (S2)
    • except when intended for inhalation or nasal administration. (S3)

    Consolidated Schedules 06 July 2026, lines 6411 to 6421

  • S3: Fluticasone furoate

    • when intended for inhalation or nasal administration;
    • except when intended for nasal administration, as an aqueous spray in the short-term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses. (S2)
    • except when intended for administration other than by inhalation or nasal administration. (S4)

    Consolidated Schedules 06 July 2026, lines 3622 to 3639

  • S2: Fluticasone furoate

    • when intended for nasal administration, as an aqueous spray, in the short-term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses; (S3)
    • except when intended for administration other than by inhalation or nasal administration. (S4)

    Consolidated Schedules 06 July 2026, lines 2033 to 2040

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles